SFGate1mon
Amneal: Q4 Earnings Snapshot
BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $31.1 million in its fourth quarter. The Bridgewater, New Jersey-based ...
Benzinga.com1mon
Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars
AvKARE revenues growing 14% due to new product launches, and Specialty revenues growing 16% driven by key branded products including CREXONT. Also Read: Generic Drug Maker Amneal Pharmaceuticals ...
Business Insider14d
Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment
In 2024, Amneal introduced a record number of new products, focusing on complex generics and biosimilars. The company’s ongoing investments in R&D and sales expansion aim to sustain long-term ...
Seeking Alpha1mon
Amneal projects $3B-$3.1B revenue in 2025 with biosimilars and CREXONT as key drivers
Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance ... about long-term CapEx and competitive positioning in new markets. Management displayed confidence, particularly ...
Investing19d
Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth
Amneal’s growth strategy heavily relies on new product launches and pipeline development. The recent launch of CREXONT has been particularly noteworthy. Analysts expect CREXONT to achieve at ...